{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:07:35Z","timestamp":1794856055198,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation for Young Scientists of Henan Province","award":["222300420261"],"award-info":[{"award-number":["222300420261"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver hepatocellular carcinoma (LIHC) ranks sixth among the most common types of cancer with a high mortality rate. Cuproptosis is a newly discovered type of cell death in tumor, which is characterized by accumulation of intracellular copper leading to the aggregation of mitochondrial lipoproteins and destabilization of proteins. Thus, understanding the exact effects of cuproptosis-related genes in LIHC and determining their prognosticvalue is critical. However, the prognostic model of LIHC based on cuproptosis-related genes has not been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Firstly, we downloaded transcriptome data and clinical information of LIHC patients from TCGA and GEO (GSE76427), respectively. We then extracted the expression of cuproptosis-related genes and established a prognostic model by lasso cox regression analysis. Afterwards, the prediction performance of the model was evaluated by Kaplan\u2013Meier survival analysis and receiver operating characteristic curve (ROC). Then, the prognostic model and the expression levels of the three genes were validated using the dataset from GEO. Subsequently, we divided LIHC patients into two subtypes by non-negative matrix factorization (NMF) classification and performed survival analysis. We constructed a Sankey plot linking different subtypes and prognostic models. Next, we calculate the drug sensitivity of each sample from patients in the high-risk group and low-risk group by the R package pRRophetic. Finally, we verified the function of LIPT1 in LIHC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using lasso cox regression analysis, we developed a prognostic risk model based on three cuproptosis-related genes (GCSH, LIPT1 and CDKN2A). Both in the training and in the test sets, the overall survival (OS) of LIHC patients in the low-risk group was significantly longer than that in the high-risk group. By performing NMF cluster, we identified two molecular subtypes of LIHC (C1 and C2), with C1 subtype having significantly longer OS and PFS than C2 subtype. The ROC analysis indicated that our model had a precisely predictive capacity for patients with LIHC. The multivariate Cox regression analysis indicated that the risk score is an independent predictor. Subsequently, we identified 71 compounds with IC50 values that differed between the high-risk and low-risk groups. Finally, we determined that knockdown of LIPT1 gene expression inhibited proliferation and invasion of hepatoma cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, we developed a novel prognostic model for hepatocellular carcinoma based on cuproptosis-related genes that can effectively predict the prognosis of LIHC patients. The model may be helpful for clinicians to make clinical decisions for patients with LIHC and provide valuable insights for individualized treatment. Two distinct subtypes of LIHC were identified based on cuproptosis-related genes, with different prognosis and immune characteristics. In addition, we verified that LIPT1 may promote proliferation, invasion and migration of LIHC cells. LIPT1 might be a new potential target for therapy of LIHC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-022-03630-1","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:02:24Z","timestamp":1664895744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-9265","authenticated-orcid":false,"given":"Cheng","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liukai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5067-1756","authenticated-orcid":false,"given":"Jiahao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"issue":"1","key":"3630_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EAFTSOT Liver","year":"2018","unstructured":"EAFTSOT Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"key":"3630_CR2","unstructured":"Organization WH: WHO report on cancer: setting priorities, investing wisely and providing care for all. 2020. Available at: https:\/\/www.who.int\/publications\/i\/item\/who-report-on-cancer-setting-priorities-investing-wisely-and-providing-care-for-all. Accessed 19 Aug 2022."},{"issue":"9","key":"3630_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/djx030","volume":"109","author":"A Jemal","year":"2017","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL. Annual report to the nation on the status of cancer 1975\u20132014 featuring survival. J Natl Cancer Inst. 2017;109(9):30.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3630_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7819-11-190","volume":"11","author":"C Duan","year":"2013","unstructured":"Duan C, Liu M, Zhang Z, Ma K, Bie P. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting milan criteria: a systematic review and meta-analysis. World J Surg Oncol. 2013;11(1):1\u20139.","journal-title":"World J Surg Oncol"},{"issue":"7","key":"3630_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/ncponc0844","volume":"4","author":"M Schwartz","year":"2007","unstructured":"Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4(7):424\u201332.","journal-title":"Nat Clin Pract Oncol"},{"issue":"36","key":"3630_CR6","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.3748\/wjg.v21.i36.10327","volume":"21","author":"K Han","year":"2015","unstructured":"Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21(36):10327.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"3630_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nchembio.72","volume":"4","author":"B-E Kim","year":"2008","unstructured":"Kim B-E, Nevitt T, Thiele DJ. Mechanisms for copper acquisition, distribution and regulation. Nat Chem Biol. 2008;4(3):176\u201385.","journal-title":"Nat Chem Biol"},{"issue":"5415","key":"3630_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.284.5415.805","volume":"284","author":"T Rae","year":"1999","unstructured":"Rae T, Schmidt P, Pufahl R, Culotta V, O\u2019Halloran VT. Undetectable intracellular free copper the requirement of a copper chaperone for superoxide dismutase. Science. 1999;284(5415):805\u20138.","journal-title":"Science"},{"issue":"2","key":"3630_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cbpa.2010.01.003","volume":"14","author":"S Lutsenko","year":"2010","unstructured":"Lutsenko S. Human copper homeostasis: a network of interconnected pathways. Curr Opin Chem Biol. 2010;14(2):211\u20137.","journal-title":"Curr Opin Chem Biol"},{"issue":"6586","key":"3630_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"issue":"6586","key":"3630_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1126\/science.abo3959","volume":"375","author":"MA Kahlson","year":"2022","unstructured":"Kahlson MA, Dixon SJ. Copper-induced cell death. Science. 2022;375(6586):1231\u20132.","journal-title":"Science"},{"issue":"5","key":"3630_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41422-022-00653-7","volume":"32","author":"D Tang","year":"2022","unstructured":"Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res. 2022;32(5):417\u20138.","journal-title":"Cell Res"},{"key":"3630_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00866-1","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang L, Zhou F. Cuproptosis a new form of programmed cell death. Cell Mol Immunol. 2022. https:\/\/doi.org\/10.1038\/s41423-022-00866-1.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"3630_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1039\/d0mt00156b","volume":"12","author":"CI Davis","year":"2020","unstructured":"Davis CI, Gu X, Kiefer RM, Ralle M, Gade TP, Brady DC. Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. Metallomics. 2020;12(12):1995\u20132008.","journal-title":"Metallomics"},{"key":"3630_CR15","volume-title":"R survival package","author":"T Therneau","year":"2013","unstructured":"Therneau T, Lumley T. R survival package. Vienna: R Core Team; 2013."},{"key":"3630_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-31245-3","volume-title":"Applied survival analysis using R","author":"DF Moore","year":"2016","unstructured":"Moore DF. Applied survival analysis using R. Cham: Springer; 2016."},{"key":"3630_CR17","volume-title":"A guide to chi-squared testing","author":"PE Greenwood","year":"1996","unstructured":"Greenwood PE, Nikulin MS. A guide to chi-squared testing. Hoboken: John Wiley and Sons; 1996."},{"key":"3630_CR18","volume-title":"Package \u2018rms\u2019","author":"FE Harrell Jr","year":"2017","unstructured":"Harrell FE Jr, Harrell MFE Jr, Hmisc D. Package \u2018rms.\u2019 Nashville: Vanderbilt University; 2017."},{"key":"3630_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume-title":"Cancer systems biology","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. In: von Stechow Louise, editor. Cancer systems biology. New York: Springer; 2018. p. 243\u201359."},{"issue":"2","key":"3630_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3102\/10769986019002111","volume":"19","author":"T-H Hsiung","year":"1994","unstructured":"Hsiung T-H, Olejnik S, Huberty CJ. Comment on a wilcox test statistic for comparing means when variances are unequal. J Educ Stat. 1994;19(2):111\u20138.","journal-title":"J Educ Stat"},{"issue":"1","key":"3630_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"3630_CR22","first-page":"1","volume":"27","author":"A Alexa","year":"2009","unstructured":"Alexa A, Rahnenf\u00fchrer J. Gene set enrichment analysis with topGO. Bioconductor Improv. 2009;27:1\u201326.","journal-title":"Bioconductor Improv"},{"issue":"9","key":"3630_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9): e107468.","journal-title":"PLoS ONE"},{"issue":"1","key":"3630_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-33677-4","volume":"8","author":"A Adamus","year":"2018","unstructured":"Adamus A, M\u00fcller P, Nissen B, Kasten A, Timm S, Bauwe H, Seitz G, Engel N. GCSH antisense regulation determines breast cancer cells\u2019 viability. Sci Rep. 2018;8(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"4","key":"3630_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10545-014-9705-8","volume":"37","author":"JA Mayr","year":"2014","unstructured":"Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid biosynthesis defects. J Inherit Metab Dis. 2014;37(4):553\u201363.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"3630_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1586\/17512433.2014.966816","volume":"7","author":"PM Bingham","year":"2014","unstructured":"Bingham PM, Stuart SD, Zachar Z. Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy. Expert Rev Clin Pharmacol. 2014;7(6):837\u201346.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"3630_CR27","first-page":"81","volume":"55","author":"L Novotny","year":"2008","unstructured":"Novotny L, Rauko P, Cojocel C. Alpha-lipoic acid-the potential for use in cancer therapy minireview. Neoplasma-Bratislava. 2008;55(2):81.","journal-title":"Neoplasma-Bratislava"},{"issue":"5","key":"3630_CR28","first-page":"1145","volume":"10","author":"EDC Al-Grawi","year":"2018","unstructured":"Al-Grawi EDC, Al-Awsi GRL. Expression of CDKN2A (P16\/Ink4a) among colorectal cancer patients: a cohort study. J Pharm Sci Res. 2018;10(5):1145\u20137.","journal-title":"J Pharm Sci Res"},{"issue":"1","key":"3630_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF03401664","volume":"3","author":"WD Foulkes","year":"1997","unstructured":"Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med. 1997;3(1):5\u201320.","journal-title":"Mol Med"},{"issue":"6","key":"3630_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clinre.2017.07.003","volume":"42","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Wang X-b, Qiu X-p, Zhang S, Wang C, Zheng F. CDKN2A promoter methylation and hepatocellular carcinoma risk: a meta-analysis. Clin Res Hepatol Gastroenterol. 2018;42(6):529\u201341.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7015","key":"3630_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316\u201323.","journal-title":"Nature"},{"issue":"2","key":"3630_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/path.3022","volume":"226","author":"GH Williams","year":"2012","unstructured":"Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352\u201364.","journal-title":"J Pathol"},{"key":"3630_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"8","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee M-H, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16INK4a) in cancer. EBioMedicine. 2016;8:30\u20139.","journal-title":"EBioMedicine"},{"key":"3630_CR34","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.1.7","author":"L Toschi","year":"2005","unstructured":"Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005. https:\/\/doi.org\/10.1517\/14796694.1.1.7.","journal-title":"Future Oncol"},{"issue":"3","key":"3630_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","volume":"54","author":"S Noble","year":"1997","unstructured":"Noble S, Goa KL. Gemcitabine. Drugs. 1997;54(3):447\u201372.","journal-title":"Drugs"},{"key":"3630_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ejmech.2018.08.055","volume":"157","author":"H Cheng","year":"2018","unstructured":"Cheng H, Huang H, Huang G. Synthesis and antitumor activity of epothilone B. Eur J Med Chem. 2018;157:925\u201334.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"3630_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/molecules23030621","volume":"23","author":"J-H Ko","year":"2018","unstructured":"Ko J-H, Lee S-G, Yang WM, Um J-Y, Sethi G, Mishra S, Shanmugam MK, Ahn KS. The application of embelin for cancer prevention and therapy. Molecules. 2018;23(3):621.","journal-title":"Molecules"},{"issue":"1","key":"3630_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11010-013-1853-x","volume":"386","author":"D-G Wang","year":"2014","unstructured":"Wang D-G, Sun Y-B, Ye F, Li W, Kharbuja P, Gao L, Zhang DY, Suo J. Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells. Mol Cell Biochem. 2014;386(1):143\u201352.","journal-title":"Mol Cell Biochem"},{"key":"3630_CR39","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1158\/1538-7445.AM2012-2265","volume":"72","author":"Z Jehan","year":"2012","unstructured":"Jehan Z, Al-obaisi KAR, Uddin S, Al-Kuraya K. Embelin induces autophagy in ovarian cancer cells. Cancer Res. 2012;72:2265\u20132265.","journal-title":"Cancer Res"},{"issue":"3","key":"3630_CR40","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.7314\/APJCP.2016.17.3.1103","volume":"17","author":"TT Kaya","year":"2016","unstructured":"Kaya TT, Turgut NH, Ataseven H, Koyluoglu G. Effects of a multikinase inhibitor motesanib (AMG 706) alone and combined with the selective DuP-697 COX-2 inhibitor on colorectal cancer cells. Asian Pac J Cancer Prev. 2016;17(3):1103\u201310.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"3630_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4254\/wjh.v7.i3.593","volume":"7","author":"K Miyanishi","year":"2015","unstructured":"Miyanishi K, Hoki T, Tanaka S, Kato J. Prevention of hepatocellular carcinoma: focusing on antioxidant therapy. World J Hepatol. 2015;7(3):593.","journal-title":"World J Hepatol"},{"key":"3630_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7891574","author":"Z Wang","year":"2016","unstructured":"Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative stress and liver cancer: etiology and therapeutic targets. Oxid Med Cell Longev. 2016. https:\/\/doi.org\/10.1155\/2016\/7891574.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"3630_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3892\/etm.2016.3282","volume":"12","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Ma S, Liu B, Liu J, Zhu R, Li M. Chrysin induces cell apoptosis via activation of the p53\/Bcl-2\/caspase-9 pathway in hepatocellular carcinoma cells. Exp Ther Med. 2016;12(1):469\u201374.","journal-title":"Exp Ther Med"},{"issue":"6","key":"3630_CR44","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/15548627.2016.1166318","volume":"12","author":"Q Huang","year":"2016","unstructured":"Huang Q, Zhan L, Cao H, Li J, Lyu Y, Guo X, Zhang J, Ji L, Ren T, An J. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy. 2016;12(6):999\u20131014.","journal-title":"Autophagy"},{"issue":"11","key":"3630_CR45","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1089\/ars.2010.3221","volume":"13","author":"JD Hayes","year":"2010","unstructured":"Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1\u2013Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713\u201348.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"3630_CR46","doi-asserted-by":"publisher","first-page":"e46310112028","DOI":"10.33448\/rsd-v10i1.12028","volume":"10","author":"C Locatelli","year":"2021","unstructured":"Locatelli C, Jardim JKB, Zancanaro V. Role of antioxidants in the treatment of hepatocellular carcinoma: integrative review. Res, Soc Dev. 2021;10(1):e46310112028\u2013e46310112028.","journal-title":"Res, Soc Dev"},{"issue":"1","key":"3630_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.03966.x","volume":"72","author":"VS Chachay","year":"2011","unstructured":"Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, Prins JB, Martin JH. Resveratrol\u2013pills to replace a healthy diet? Br J Clin Pharmacol. 2011;72(1):27\u201338.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3630_CR48","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3390\/molecules19021592","volume":"19","author":"Q Xie","year":"2014","unstructured":"Xie Q, Yang Y, Wang Z, Chen F, Zhang A, Liu C. Resveratrol-4-O-D-(2\u2019-galloyl)-glucopyranoside isolated from polygonum cuspidatum exhibits anti-hepatocellular carcinoma viability by inducing apoptosis via the JNK and ERK pathway. Molecules. 2014;19(2):1592\u2013602.","journal-title":"Molecules"},{"issue":"6","key":"3630_CR49","doi-asserted-by":"publisher","first-page":"101042831769912","DOI":"10.1177\/1010428317699127","volume":"39","author":"HA Aglan","year":"2017","unstructured":"Aglan HA, Ahmed HH, El-Toumy SA, Mahmoud NS. Gallic acid against hepatocellular carcinoma: an integrated scheme of the potential mechanisms of action from in vivo study. Tumor Biol. 2017;39(6):1010428317699127.","journal-title":"Tumor Biol"},{"key":"3630_CR50","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.biopha.2016.10.048","volume":"84","author":"KG Lima","year":"2016","unstructured":"Lima KG, Krause GC, Schuster AD, Catarina AV, Basso BS, De Mesquita FC, Pedrazza L, Marczak ES, Martha BA, Nunes FB. Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells. Biomed Pharmacother. 2016;84:1282\u201390.","journal-title":"Biomed Pharmacother"},{"issue":"26","key":"3630_CR51","doi-asserted-by":"publisher","first-page":"42789","DOI":"10.18632\/oncotarget.17050","volume":"8","author":"L Sakka","year":"2017","unstructured":"Sakka L, Del\u00e9tage N, Chalus M, Aissouni Y, Sylvain-Vidal V, Gobron S, Coll G. Assessment of citalopram and escitalopram on neuroblastoma cell lines: cell toxicity and gene modulation. Oncotarget. 2017;8(26):42789.","journal-title":"Oncotarget"},{"issue":"5","key":"3630_CR52","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/cancers12051184","volume":"12","author":"Y-C Liu","year":"2020","unstructured":"Liu Y-C, Chen VC-H, Lu M-L, Lee M-J, McIntyre RS, Majeed A, Lee Y, Chen Y-L. The association between selective serotonin reuptake inhibitors (SSRIs) use and the risk of bladder cancer: a nationwide population-based cohort study. Cancers. 2020;12(5):1184.","journal-title":"Cancers"},{"issue":"11","key":"3630_CR53","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s12272-016-0766-0","volume":"40","author":"E Ahmadian","year":"2017","unstructured":"Ahmadian E, Eftekhari A, Fard JK, Babaei H, Nayebi AM, Mohammadnejad D, Eghbal MA. In vitro and in vivo evaluation of the mechanisms of citalopram-induced hepatotoxicity. Arch Pharmacal Res. 2017;40(11):1296\u2013313.","journal-title":"Arch Pharmacal Res"},{"issue":"5","key":"3630_CR54","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/ijms23052711","volume":"23","author":"M Taler","year":"2022","unstructured":"Taler M, Gil-Ad I, Brener I, Hornfeld SH, Weizman A. Complex effects of sertraline and citalopram on in vitro murine breast cancer proliferation and on in vivo progression and anxiety level. Int J Mol Sci. 2022;23(5):2711.","journal-title":"Int J Mol Sci"},{"issue":"410","key":"3630_CR55","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment implications for immunotherapy. Sci Transl Med. 2017;9(410):5616.","journal-title":"Sci Transl Med"},{"key":"3630_CR56","volume-title":"Renin-Angiotensin System-Past Present and Future","author":"E Taskin","year":"2017","unstructured":"Taskin E, Guven C. Local renin-angiotensin system at liver and crosstalk with hepatic diseases. In: Tolekova Anna Naidenova, editor. Renin-Angiotensin System-Past Present and Future. London: IntechOpen; 2017."},{"key":"3630_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111868","volume":"141","author":"H-F Zhang","year":"2021","unstructured":"Zhang H-F, Gao X, Wang X, Chen X, Huang Y, Wang L, Xu Z-W. The mechanisms of renin\u2013angiotensin system in hepatocellular carcinoma: from the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures. Biomed Pharmacother. 2021;141: 111868.","journal-title":"Biomed Pharmacother"},{"key":"3630_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.736361","volume":"12","author":"M Almutlaq","year":"2021","unstructured":"Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. The effect of local renin angiotensin system in the common types of cancer. Front Endocrinol. 2021;12: 736361.","journal-title":"Front Endocrinol"},{"key":"3630_CR59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21037\/atm.2019.11.131","volume":"7","author":"L-H Feng","year":"2019","unstructured":"Feng L-H, Sun H-C, Zhu X-D, Zhang S-Z, Li K-S, Li X-L, Li Y, Tang Z-Y. Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy. Ann Transl Med. 2019;7:23.","journal-title":"Ann Transl Med"},{"issue":"12","key":"3630_CR60","doi-asserted-by":"publisher","first-page":"16291","DOI":"10.1096\/fj.202001639R","volume":"34","author":"LN Song","year":"2020","unstructured":"Song LN, Liu JY, Shi TT, Zhang YC, Xin Z, Cao X, Yang JK. Angiotensin-(1\u20137), the product of ACE2 ameliorates NAFLD by acting through its receptor mas to regulate hepatic mitochondrial function and glycolipid metabolism. FASEB J. 2020;34(12):16291\u2013306.","journal-title":"FASEB J"},{"issue":"5","key":"3630_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2020.12071","volume":"20","author":"Y Ji","year":"2020","unstructured":"Ji Y, Chen H, Gow W, Ma L, Jin Y, Hui B, Yang Z, Wang Z. Potential biomarkers Ang II\/AT1R and S1P\/S1PR1 predict the prognosis of hepatocellular carcinoma. Oncol Lett. 2020;20(5):1\u20131.","journal-title":"Oncol Lett"},{"issue":"3","key":"3630_CR62","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/cells10030575","volume":"10","author":"H Takagi","year":"2021","unstructured":"Takagi H, Kaji K, Nishimura N, Ishida K, Ogawa H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T. The angiotensin II receptor blocker losartan sensitizes human liver cancer cells to lenvatinib-mediated cytostatic and angiostatic effects. Cells. 2021;10(3):575.","journal-title":"Cells"},{"issue":"1","key":"3630_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/JCI16645","volume":"112","author":"K Egami","year":"2003","unstructured":"Egami K, Murohara T, Shimada T, Sasaki K-i, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112(1):67\u201375.","journal-title":"J Clin Invest"},{"issue":"11","key":"3630_CR64","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1111\/jgh.12988","volume":"30","author":"A Facciorusso","year":"2015","unstructured":"Facciorusso A, Del Prete V, Crucinio N, Muscatiello N, Carr BI, Di Leo A, Barone M. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol. 2015;30(11):1643\u201350.","journal-title":"J Gastroenterol Hepatol"},{"key":"3630_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdx263.002","volume":"28","author":"G Marisi","year":"2017","unstructured":"Marisi G, Passardi A, Scartozzi M, Silvestris N, Valgiusti M, Ulivi P, Faloppi L, Brunetti O, Giovanni LF, Gardini AC. Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Ann Oncol. 2017;28:1\u20132.","journal-title":"Ann Oncol"},{"issue":"7","key":"3630_CR66","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1177\/2050640617695698","volume":"5","author":"M Pinter","year":"2017","unstructured":"Pinter M, Weinmann A, W\u00f6rns M-A, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M. Use of inhibitors of the renin\u2013angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterol J. 2017;5(7):987\u201396.","journal-title":"United European Gastroenterol J"},{"issue":"1\u20133","key":"3630_CR67","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ejphar.2007.11.016","volume":"579","author":"Y Takeshita","year":"2008","unstructured":"Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, Matsuzawa-Nagata N, Kaneko S. Cross talk of tumor necrosis factor-\u03b1 and the renin\u2013angiotensin system in tumor necrosis factor-\u03b1-induced plasminogen activator inhibitor-1 production from hepatocytes. Eur J Pharmacol. 2008;579(1\u20133):426\u201332.","journal-title":"Eur J Pharmacol"},{"issue":"21","key":"3630_CR68","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.3748\/wjg.15.2579","volume":"15","author":"RM Pereira","year":"2009","unstructured":"Pereira RM, dos Santos RAS, da Costa Dias FL, Teixeira MM. E silva ACS: renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol. 2009;15(21):2579.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3630_CR69","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1258\/ebm.2011.010375","volume":"236","author":"MK Munshi","year":"2011","unstructured":"Munshi MK, Uddin MN, Glaser SS. The role of the renin\u2013angiotensin system in liver fibrosis. Exp Biol Med. 2011;236(5):557\u201366.","journal-title":"Exp Biol Med"},{"issue":"3\u20134","key":"3630_CR70","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000343851","volume":"2","author":"T Sakurai","year":"2013","unstructured":"Sakurai T, Kudo M. Molecular link between liver fibrosis and hepatocellular carcinoma. Liver cancer. 2013;2(3\u20134):365.","journal-title":"Liver cancer"},{"key":"3630_CR71","doi-asserted-by":"publisher","DOI":"10.1177\/1470320316628717","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Li N, Li F, Zhou Z, Han Q, Lv Y, Sang J, Liu Z. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. J Renin-Angiotensin-Aldosterone Syst. 2016. https:\/\/doi.org\/10.1177\/1470320316628717.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"2","key":"3630_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajhg.2017.07.001","volume":"101","author":"F Habarou","year":"2017","unstructured":"Habarou F, Hamel Y, Haack TB, Feichtinger RG, Lebigot E, Marquardt I, Busiah K, Laroche C, Madrange M, Grisel C. Biallelic mutations in LIPT2 cause a mitochondrial lipoylation defect associated with severe neonatal encephalopathy. Am J Hum Genet. 2017;101(2):283\u201390.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3630_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-8-192","volume":"8","author":"Y Soreze","year":"2013","unstructured":"Soreze Y, Boutron A, Habarou F, Barnerias C, Nonnenmacher L, Delpech H, Mamoune A, Chr\u00e9tien D, Hubert L, Bole-Feysot C. Mutations in human lipoyltransferase gene LIPT1cause a leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. Orphanet J Rare Dis. 2013;8(1):1\u20139.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"3630_CR74","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/hmg\/ddt585","volume":"23","author":"F Tort","year":"2014","unstructured":"Tort F, Ferrer-Cort\u00e8s X, Thi\u00f3 M, Navarro-Sastre A, Matalonga L, Quintana E, Bujan N, Arias A, Garc\u00eda-Villoria J, Acquaviva C. Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with a specific lipoylation defect of the 2-ketoacid dehydrogenase complexes. Hum Mol Genet. 2014;23(7):1907\u201315.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"3630_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3892\/or.2020.7853","volume":"45","author":"Y Chen","year":"2021","unstructured":"Chen Y, Xu T, Xie F, Wang L, Liang Z, Li D, Liang Y, Zhao K, Qi X, Yang X. Evaluating the biological functions of the prognostic genes identified by the pathology atlas in bladder cancer. Oncol Rep. 2021;45(1):191\u2013201.","journal-title":"Oncol Rep"},{"key":"3630_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.930041","author":"H Lv","year":"2022","unstructured":"Lv H, Liu X, Zeng X, Liu Y, Zhang C, Zhang Q, Xu J. Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in melanoma. Front pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.930041.","journal-title":"Front pharmacol"},{"issue":"6127","key":"3630_CR77","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"}],"updated-by":[{"DOI":"10.1186\/s12967-025-07008-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03630-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03630-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:02:28Z","timestamp":1778331748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-022-03630-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03630-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-025-07008-x","URL":"https:\/\/doi.org\/10.1186\/s12967-025-07008-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}